SGSM1 Antibody

What is SGSM1 and why is it important in research?

SGSM1 (Small G Protein Signaling Modulator 1) is a protein that functions as a modulator of small G protein signaling pathways. The protein is also known by several other names including Mob, SMS1, MOB1, and TMEM23 . It has been identified as a potential prognostic biomarker in certain cancers, particularly lower-grade gliomas (LGGs) . Research has shown that SGSM1 expression correlates with immune response and infiltration in gliomas, making it an interesting target for cancer research .

The significance of SGSM1 lies in:

• Its role in cellular signaling pathways

• Its potential as a prognostic biomarker in gliomas

• Its correlation with immune infiltration in tumor microenvironments

• Its largely unexplored functions in various physiological and pathological processes

What are the basic characteristics of commercially available SGSM1 antibodies?

Available SGSM1 antibodies exhibit various characteristics depending on their source and design:

When selecting an SGSM1 antibody, researchers should consider the specific target region (N-terminal, middle region, or C-terminal) and validate reactivity for their species of interest .

What experimental applications are SGSM1 antibodies suitable for?

SGSM1 antibodies have been validated for multiple experimental applications:

• Western Blotting (WB): Most commonly used application, with recommended dilutions ranging from 1:300 to 1:600 . Positive WB detection has been reported in mouse testis tissue .

• Immunohistochemistry (IHC): Validated for tissue sections with recommended dilutions of 1:50 to 1:200 . Positive IHC signals have been detected in mouse skin tissue . Antigen retrieval is typically performed with TE buffer (pH 9.0) or alternatively with citrate buffer (pH 6.0) .

• ELISA: Available for quantitative detection of SGSM1 .

• Immunofluorescence (IF): Both cellular and tissue IF applications have been validated for some antibodies .

Researchers should note that optimal dilutions are sample-dependent, and each antibody should be titrated in the specific testing system to obtain optimal results .

How does SGSM1 expression correlate with immune infiltration in lower-grade gliomas?

Studies have revealed complex relationships between SGSM1 expression and immune infiltration in lower-grade gliomas:

• Differential immune cell infiltration: SGSM1 expression shows significant correlations with various immune cell populations. High SGSM1 expression has been associated with increased infiltration of mast cells (P = 0.011), NK CD56bright cells (P < 0.001), T follicular helper cells (P < 0.001), Th1 cells (P = 0.042), TReg cells (P < 0.001), and plasmacytoid dendritic cells (P = 0.001) .

• Negative correlations: Low SGSM1 expression correlates with increased infiltration of activated dendritic cells (P < 0.001), cytotoxic cells (P < 0.001), eosinophils (P < 0.001), immature dendritic cells (P < 0.001), macrophages (P < 0.001), neutrophils (P < 0.001), NK CD56dim cells (P = 0.001), NK cells (P < 0.001), T cells (P < 0.001), and T gamma delta cells (P < 0.001) .

• Functional associations: Gene set enrichment analysis (GSEA) has shown that SGSM1 expression is associated with immune-related pathways. Low SGSM1 expression correlates with enrichment in pathways related to lymphocyte-mediated immunity, phagocytosis, humoral immune response, immunoglobulin production, and immune response regulating signaling pathways .

These findings suggest that SGSM1 may play a role in modulating the immune microenvironment in gliomas, potentially influencing tumor progression and patient outcomes.

What methodologies can be used to investigate SGSM1's prognostic value in cancer research?

To investigate SGSM1's prognostic value in cancer, researchers can employ several methodological approaches:

These methodologies provide a comprehensive framework for investigating SGSM1's prognostic value in cancer research.

What are the challenges in antibody-based detection of SGSM1 in different sample types?

Detecting SGSM1 using antibodies presents several challenges across different sample types:

• Tissue-specific expression levels:

  • SGSM1 expression varies across tissues, with positive WB detection reported in mouse testis tissue and positive IHC in mouse skin tissue

  • Low expression in certain tissues may require signal amplification techniques

  • Optimization of sample preparation protocols for each tissue type is necessary

• Specificity concerns:

  • Multiple names and aliases for the protein (SGMS1, Mob, SMS1, MOB1, TMEM23) can lead to confusion in antibody selection

  • Potential cross-reactivity with related proteins requires thorough validation

  • Confirmation of specificity through knockout/knockdown controls is recommended

• Technical considerations:

  • Antigen retrieval methods significantly impact detection in fixed tissues (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • Optimal antibody dilutions vary widely (1:50-1:200 for IHC, 1:300-1:600 for WB)

  • Sample-dependent optimization is necessary for each experimental system

• Subcellular localization:

  • Detection of membrane-associated proteins may require specific lysis and extraction protocols

  • Preservation of protein complexes and interaction partners might be necessary for functional studies

  • Specific fixation techniques may be required for immunofluorescence applications

To address these challenges, researchers should:

• Validate antibodies with positive and negative controls

• Optimize protocols for each sample type and application

• Consider using multiple antibodies targeting different epitopes

• Complement antibody-based detection with molecular techniques (RT-PCR, RNA-seq)

What are the optimal conditions for Western Blot detection of SGSM1?

Optimizing Western Blot conditions for SGSM1 detection requires careful consideration of several parameters:

• Sample preparation:

  • For tissue samples: Mouse testis tissue has shown positive results

  • Lysis buffer: RIPA buffer supplemented with protease inhibitors is commonly used

  • Sample amount: 20-50 μg of total protein per lane is typically sufficient

• Gel electrophoresis:

  • Percentage: 8-10% SDS-PAGE gels are recommended for the 130 kDa SGSM1 protein

  • Running conditions: 100-120V for optimal separation

• Transfer conditions:

  • Method: Wet transfer is preferred for large proteins

  • Buffer: Tris-glycine with 20% methanol

  • Duration: 90-120 minutes at 100V (4°C) or overnight at 30V

• Blocking and antibody incubation:

  • Blocking: 5% non-fat milk or BSA in TBST for 1 hour at room temperature

  • Primary antibody:

    • Dilution: 1:300-1:600 in blocking buffer

    • Incubation: Overnight at 4°C with gentle agitation

  • Washing: 3-5 times with TBST, 5-10 minutes each

  • Secondary antibody:

    • Anti-rabbit HRP conjugate at 1:2000-1:5000

    • Incubation: 1-2 hours at room temperature

• Detection:

  • Enhanced chemiluminescence (ECL) substrates

  • Exposure time: Start with 30 seconds and adjust as needed

  • Expected molecular weight: 130 kDa

Troubleshooting tips:

• If background is high, increase washing steps or reduce antibody concentration

• If signal is weak, increase protein loading, antibody concentration, or incubation time

• For multiple bands, optimize SDS concentration and reducing agent

How can SGSM1 antibodies be validated for research applications?

Comprehensive validation of SGSM1 antibodies is crucial for ensuring reliable research results:

• Western Blot validation:

  • Confirm correct molecular weight (130 kDa for SGSM1 , 48.6 kDa for SGMS1 )

  • Test in multiple positive tissue samples (e.g., mouse testis )

  • Include negative controls (tissues with low expression)

  • Validate with knockout/knockdown samples when available

• Immunohistochemistry validation:

  • Compare different antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • Test a range of antibody dilutions (1:50-1:200)

  • Include positive control tissues (e.g., mouse skin )

  • Perform blocking peptide competition assays to confirm specificity

• Cross-reactivity assessment:

  • Test reactivity across multiple species (human, mouse, rat, etc.)

  • Evaluate sequence homology of immunogen peptides across species

  • Consider potential cross-reactivity with related proteins

• Reproducibility testing:

  • Test multiple antibody lots

  • Perform replicate experiments with standardized protocols

  • Document batch-to-batch variation

• Orthogonal validation:

  • Compare results with alternative detection methods (RNA-seq, RT-PCR)

  • Correlate protein expression with mRNA levels

  • Use multiple antibodies targeting different epitopes

Validation criteria for publication:

• Signal at correct molecular weight

• Reproducible staining pattern across multiple samples

• Consistency with known biology and expression patterns

• Appropriate controls demonstrating specificity

What advanced applications are emerging for SGSM1 antibodies in cancer research?

SGSM1 antibodies are being utilized in increasingly sophisticated applications in cancer research:

• Prognostic biomarker development:

  • SGSM1 has been identified as a prognostic biomarker in lower-grade gliomas

  • Antibody-based detection methods can stratify patients based on expression levels

  • Integration with machine learning approaches for improved prognostic models

• Immune microenvironment characterization:

  • Investigation of relationships between SGSM1 expression and immune cell infiltration

  • Multiplex immunohistochemistry to simultaneously detect SGSM1 and immune markers

  • Spatial transcriptomics combined with antibody-based imaging

• Therapeutic target identification:

  • Screening for potential drug targets in SGSM1-related pathways

  • Development of antibody-drug conjugates targeting SGSM1-expressing cells

  • Combination with checkpoint inhibitors based on immune correlation data

• Functional studies:

  • Antibody-mediated inhibition of SGSM1 function

  • Co-immunoprecipitation to identify interaction partners

  • ChIP-seq applications to investigate transcriptional regulation

• Novel antibody engineering approaches:

  • Development of structure-sequence diffusion models (like Antibody-SGM) for improved antibody design

  • Generation of full-atom native-like antibodies through innovative computational methods

  • Optimization of antibody properties through active inpainting learning

These emerging applications highlight the expanding role of SGSM1 antibodies in cancer research, from basic mechanistic studies to clinical biomarker development and therapeutic innovation.

What are common troubleshooting strategies for inconsistent SGSM1 antibody results?

When facing inconsistent results with SGSM1 antibodies, researchers can implement the following troubleshooting strategies:

• Western Blot issues:

  • No signal: Increase antibody concentration, extend incubation time, verify protein transfer, check sample integrity

  • Multiple bands: Optimize sample preparation (fresh protease inhibitors), increase stringency of washing, verify antibody specificity

  • High background: Increase blocking time/concentration, reduce antibody concentration, extend washing steps

  • Incorrect molecular weight: Verify antibody specificity, check buffer conditions, ensure complete denaturation

• Immunohistochemistry challenges:

  • Weak or no staining: Optimize antigen retrieval (compare TE buffer pH 9.0 vs. citrate buffer pH 6.0) , increase antibody concentration, extend incubation time

  • High background: Increase blocking, reduce antibody concentration, extend washing steps

  • Non-specific staining: Use antigen pre-adsorption controls, optimize tissue fixation, employ alternative blocking reagents

• Antibody-specific considerations:

  • Batch-to-batch variation: Test new lots alongside previously validated antibodies

  • Storage issues: Ensure proper storage at -20°C, avoid repeated freeze-thaw cycles, consider aliquoting

  • Cross-reactivity: Verify specificity with peptide competition assays, use knockout/knockdown controls

• Protocol optimization matrix:

• Documentation practices:

  • Maintain detailed laboratory notebooks

  • Record all experimental conditions and reagent information

  • Document lot numbers and dates of antibody preparation

How can researchers ensure reproducibility in SGSM1 antibody-based experiments?

Ensuring reproducibility in SGSM1 antibody-based experiments requires systematic approaches:

• Standardized protocols:

  • Develop detailed, step-by-step protocols with precise measurements and timing

  • Include all relevant experimental conditions, including buffer compositions and incubation temperatures

  • Create visual workflow diagrams for complex procedures

• Antibody validation and characterization:

  • Document antibody source, catalog number, lot number, and RRID (Research Resource Identifier)

  • Validate each antibody lot before use in critical experiments

  • Characterize antibody performance across different applications and sample types

• Controls implementation:

  • Include positive controls (tissues with known expression, e.g., mouse testis for WB, mouse skin for IHC)

  • Incorporate negative controls (secondary antibody only, isotype controls)

  • When possible, use genetic controls (knockdown/knockout samples)

• Data analysis standardization:

  • Pre-establish quantification methods and statistical approaches

  • Use multiple approaches to quantify expression (e.g., densitometry and image analysis)

  • Implement blinding procedures when appropriate

• Reporting standards:

  • Follow field-specific guidelines (e.g., MDAR - Materials, Design, Analysis and Reporting)

  • Report all experimental details necessary for replication

  • Share raw data and analysis workflows when possible

• Validation across platforms:

  • Confirm key findings using alternative detection methods

  • Replicate critical experiments in different laboratory environments

  • Verify results using antibodies targeting different epitopes of SGSM1

Implementing these practices will significantly enhance the reproducibility of SGSM1 antibody-based experiments and increase confidence in research findings.

How might computational approaches enhance SGSM1 antibody design and development?

Computational approaches are revolutionizing antibody design, with implications for SGSM1 research:

• Score-based generative models:

  • Antibody-SGM and similar diffusion models enable joint structure-sequence design

  • These models integrate sequence-specific attributes and functional properties into the generation process

  • The ability to generate full-atom native-like antibodies starting from random sequences and structural properties

• Antigen-specific conditional generation:

  • Development of computational methods for antigen-specific antibody design

  • Focus on complementarity-determining regions (CDRs) for optimizing existing antibodies

  • Potential application to generate SGSM1-specific antibodies with enhanced properties

• Validation with AlphaFold:

  • Use of AlphaFold to validate computationally designed antibodies

  • High concordance between generated structures and AlphaFold predictions (over 70% with RMSD values below 2)

  • Integration of AlphaFold predictions into antibody design pipelines

• Active learning approaches:

  • Optimization of protein function through active inpainting learning

  • Simultaneous sequence and structure optimization for enhanced antibody properties

  • Application to SGSM1 antibodies for improved specificity and affinity

• Epitope mapping and optimization:

  • Computational prediction of optimal SGSM1 epitopes for antibody targeting

  • Design of antibodies against conserved regions for cross-species reactivity

  • Identification of epitopes that distinguish SGSM1 from related proteins

These computational approaches offer tremendous potential for enhancing SGSM1 antibody design, potentially leading to reagents with improved specificity, affinity, and cross-reactivity profiles.

What emerging roles might SGSM1 play in immunotherapy research?

SGSM1's correlation with immune infiltration suggests potential roles in immunotherapy research:

• Biomarker for immunotherapy response:

  • SGSM1 expression levels could predict response to immune checkpoint inhibitors

  • The negative correlation with immune checkpoints suggests potential complementary targeting strategies

  • Integration into multifactorial prediction models for immunotherapy outcomes

• Tumor microenvironment modulation:

  • SGSM1's differential association with immune cell populations suggests a role in shaping the tumor immune landscape

  • Potential target for reprogramming the immunosuppressive microenvironment

  • Combinatorial approaches targeting SGSM1 and immune checkpoints

• Novel therapeutic target development:

  • Development of antibody-drug conjugates targeting SGSM1-expressing cells

  • Bispecific antibodies engaging both SGSM1 and immune effector cells

  • CAR-T cell approaches utilizing SGSM1 as a target antigen

• Mechanistic studies:

  • Investigation of SGSM1's role in immune cell signaling and function

  • Exploration of potential direct interactions with immune regulatory pathways

  • Understanding how SGSM1 expression modulates response to immunotherapy

• Clinical trial stratification:

  • Use of SGSM1 expression as a stratification factor in immunotherapy trials

  • Development of companion diagnostics based on SGSM1 detection

  • Personalized immunotherapy approaches based on SGSM1 status

These emerging roles highlight the potential significance of SGSM1 in the rapidly evolving field of immunotherapy research.